Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 7/20 | 0.36 |
| ▸ | CNR1 | P21554 | 6/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TOP1 | P11387 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10435583 | 0.99 | CHRM1 (0.41) | CHRM1LMNAMAOBCNR2CNR1 | |
| SCHEMBL6422784 | 0.80 | AURKA (0.35) | KDM4E | |
| SCHEMBL9404717 | 0.78 | KDM4E (0.44) | KDM4ETOP1 | |
| SCHEMBL25374867 | 0.70 | — | — | |
| Water SCHEMBL10433543 | 0.69 | TOP2A (0.45) | CHRM1LMNACNR1KDM4ETOP1 | |
| SCHEMBL2183758 | 0.69 | MCL1 (0.49) | CHRM1LMNACNR2CNR1KDM4E | |
| SCHEMBL19971597 | 0.69 | TOP2A (0.48) | CHRM1LMNAMAOBKDM4ETOP1 | |
| SCHEMBL10578053 | 0.67 | CHRM1 (0.44) | CHRM1LMNAKDM4E | |
| SCHEMBL6167019 | 0.66 | CNR2 (0.68) | CNR2CNR1KDM4E | |
| SCHEMBL483174 | 0.66 | CNR2 (0.68) | CNR2CNR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-6016560-A | — | — | None | — | — | JP | disclosed |
| JP-6016560-A | — | — | None | — | — | JP | disclosed |
| JP-6016673-A | — | — | None | — | — | JP | disclosed |
| CN-111110641-B | Levofloxacin tablet composition and preparation method thereof | 长春海悦药业股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
| US-9012419-B2 | Methods and compositions related to eosinophil regulation | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2015-04-21 | — | — | US | disclosed |
| US-8753875-B2 | Compositions and means for diagnosing microbial infections | STATENS SERUM INSTITUT (DK) | 2014-06-17 | — | — | US | disclosed |
| US-7745432-B2 | (1,10b-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo[1,5 C][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-06-29 | — | — | US | disclosed |
| US-20100016410-A1 | Methods and Compositions Related to Eosinophil Regulation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-01-21 | — | — | US | disclosed |
| US-20090068696-A1 | COMPOSITIONS AND MEANS FOR DIAGNOSING MICROBIAL INFECTIONS | STATENS SERUM INSTITUT | 2009-03-12 | — | — | US | disclosed |
| US-20090048242-A1 | (1,10B-DIHYDRO-2-(AMINOALKYL-PHENYL)-5H-PYRAZOLO[1,5 C][1,3]BENZOXAZIN-5-YL)PHENYL METHANONE DERIVATIVES AS HIV VIRAL REPLICATION INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-02-19 | — | — | US | disclosed |
| JP-H0616673-A | 7-OXO-7H-PYRIDO(1,2,3-DE)(1,4)BENZOXADINE-6-CAROXYLIC ACID AND ITS ESTER | BAYER AG | 1994-01-25 | — | — | JP | disclosed |
| EP-0357047-B1 | Spiro compounds | DAIICHI SEIYAKU CO (JP) | 1993-11-03 | — | — | EP | disclosed |
| CN-1077886-A | Medicinal 7-oxo-7H-pyrido [1,2,3-de]-[1,4] benzoxazine-6-formic acid class and ester thereof | BAYER AG (DE) | 1993-11-03 | — | — | CN | disclosed |
| CN-1077886-A | Medicinal 7-oxo-7H-pyrido [1,2,3-de]-[1,4] benzoxazine-6-formic acid class and ester thereof | BAYER AG (DE) | 1993-11-03 | — | — | CN | disclosed |
| EP-0563733-A1 | Use of 7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxacin-6-carboxylic acid- and esters for the manufacture of a medicament for the treatment of viral diseases | BAYER AG (DE) | 1993-10-06 | — | — | EP | disclosed |
| EP-0563733-A1 | Use of 7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxacin-6-carboxylic acid- and esters for the manufacture of a medicament for the treatment of viral diseases | BAYER AG (DE) | 1993-10-06 | — | — | EP | disclosed |
| EP-0563732-A1 | 7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazinecarboxylic acids and esters and their use as antiviral agents | BAYER AG (DE) | 1993-10-06 | — | — | EP | disclosed |
| EP-0529688-A2 | Azaspiro n,m alkanes and diazaspiro n,m -alkanes | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-03-03 | — | — | EP | disclosed |
| EP-0357047-A1 | Spiro compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1990-03-07 | — | — | EP | disclosed |
| EP-0343560-A2 | Isoindoline derivative | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1989-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048242-A1 | (1,10B-DIHYDRO-2-(AMINOALKYL-PHENYL)-5H-PYRAZOLO[1,5 C][1,3]BENZOXAZIN-5-YL)PHENYL METHANONE DERIVATIVES AS HIV VIRAL REPLICATION INHIBITORS | POLRMT, MCM5, SAMHD1 | CHRM1 4408/4885LMNA 1309/4885MAOB 982/4885 |
| US-20100016410-A1 | Methods and Compositions Related to Eosinophil Regulation | EPX, CCL11, ELANE | CHRM1 4499/4885LMNA 3114/4885MAOB 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.